Cargando…
Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach
The present study aimed to work out a peptide-based multi-epitope vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We predicted different B-cell and T-cell epitopes by using the Immune Epitopes Database (IEDB). Homology modeling of the construct was done using SWISS-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565012/ https://www.ncbi.nlm.nih.gov/pubmed/32731461 http://dx.doi.org/10.3390/vaccines8030423 |
_version_ | 1783595843811540992 |
---|---|
author | Rahman, Noor Ali, Fawad Basharat, Zarrin Shehroz, Muhammad Khan, Muhammad Kazim Jeandet, Philippe Nepovimova, Eugenie Kuca, Kamil Khan, Haroon |
author_facet | Rahman, Noor Ali, Fawad Basharat, Zarrin Shehroz, Muhammad Khan, Muhammad Kazim Jeandet, Philippe Nepovimova, Eugenie Kuca, Kamil Khan, Haroon |
author_sort | Rahman, Noor |
collection | PubMed |
description | The present study aimed to work out a peptide-based multi-epitope vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We predicted different B-cell and T-cell epitopes by using the Immune Epitopes Database (IEDB). Homology modeling of the construct was done using SWISS-MODEL and then docked with different toll-like-receptors (TLR4, TLR7, and TLR8) using PatchDock, HADDOCK, and FireDock, respectively. From the overlapped epitopes, we designed five vaccine constructs C1–C5. Based on antigenicity, allergenicity, solubility, different physiochemical properties, and molecular docking scores, we selected the vaccine construct 1 (C1) for further processing. Docking of C1 with TLR4, TLR7, and TLR8 showed striking interactions with global binding energy of −43.48, −65.88, and −60.24 Kcal/mol, respectively. The docked complex was further simulated, which revealed that both molecules remain stable with minimum RMSF. Activation of TLRs induces downstream pathways to produce pro-inflammatory cytokines against viruses and immune system simulation shows enhanced antibody production after the booster dose. In conclusion, C1 was the best vaccine candidate among all designed constructs to elicit an immune response SARS-CoV-2 and combat the coronavirus disease (COVID-19). |
format | Online Article Text |
id | pubmed-7565012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75650122020-10-26 Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach Rahman, Noor Ali, Fawad Basharat, Zarrin Shehroz, Muhammad Khan, Muhammad Kazim Jeandet, Philippe Nepovimova, Eugenie Kuca, Kamil Khan, Haroon Vaccines (Basel) Article The present study aimed to work out a peptide-based multi-epitope vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We predicted different B-cell and T-cell epitopes by using the Immune Epitopes Database (IEDB). Homology modeling of the construct was done using SWISS-MODEL and then docked with different toll-like-receptors (TLR4, TLR7, and TLR8) using PatchDock, HADDOCK, and FireDock, respectively. From the overlapped epitopes, we designed five vaccine constructs C1–C5. Based on antigenicity, allergenicity, solubility, different physiochemical properties, and molecular docking scores, we selected the vaccine construct 1 (C1) for further processing. Docking of C1 with TLR4, TLR7, and TLR8 showed striking interactions with global binding energy of −43.48, −65.88, and −60.24 Kcal/mol, respectively. The docked complex was further simulated, which revealed that both molecules remain stable with minimum RMSF. Activation of TLRs induces downstream pathways to produce pro-inflammatory cytokines against viruses and immune system simulation shows enhanced antibody production after the booster dose. In conclusion, C1 was the best vaccine candidate among all designed constructs to elicit an immune response SARS-CoV-2 and combat the coronavirus disease (COVID-19). MDPI 2020-07-28 /pmc/articles/PMC7565012/ /pubmed/32731461 http://dx.doi.org/10.3390/vaccines8030423 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rahman, Noor Ali, Fawad Basharat, Zarrin Shehroz, Muhammad Khan, Muhammad Kazim Jeandet, Philippe Nepovimova, Eugenie Kuca, Kamil Khan, Haroon Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach |
title | Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach |
title_full | Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach |
title_fullStr | Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach |
title_full_unstemmed | Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach |
title_short | Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach |
title_sort | vaccine design from the ensemble of surface glycoprotein epitopes of sars-cov-2: an immunoinformatics approach |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565012/ https://www.ncbi.nlm.nih.gov/pubmed/32731461 http://dx.doi.org/10.3390/vaccines8030423 |
work_keys_str_mv | AT rahmannoor vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT alifawad vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT basharatzarrin vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT shehrozmuhammad vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT khanmuhammadkazim vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT jeandetphilippe vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT nepovimovaeugenie vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT kucakamil vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach AT khanharoon vaccinedesignfromtheensembleofsurfaceglycoproteinepitopesofsarscov2animmunoinformaticsapproach |